Chronic pain remains one of medicine’s most persistent challenges. For millions of patients, standard treatments such as opioids, anti-inflammatory drugs, or nerve blocks provide incomplete relief or introduce serious risks. As a result, some researchers are exploring approaches that deviate from known pharmacological pathways for analgesia. Once sidelined from mainstream medicine, psychedelics are now being studied as potential agents for pain relief due to how they may alter pain perception and emotional suffering linked to long-term conditions, with growing numbers of medical centers investing in this developing area of research.

Research on psychedelics comes with regulatory requirements and safety considerations that medical centers must navigate, making interdisciplinary collaboration essential. Centers such as Massachusetts General Hospital, NYU Langone Health, and the Cleveland Clinic combine clinical pain programs with neuroimaging and psychiatry expertise. Their studies investigate how substances like psilocybin and ketamine affect brain circuits involved in pain processing, rather than promote them as simple treatments. Thoroughly understanding the molecular, cellular, neural, and psychological effects of psychedelics and conducting rigorous clinical trials are necessary for safety, accuracy, and credibility (1-7).

Modern pain research recognizes that pain is not purely a physical signal from injured tissue. Chronic pain often involves lasting changes in brain networks related to emotion, attention, and memory. At institutions like Stanford University and UC San Diego, researchers use brain scans to study whether psychedelics can temporarily “reset” rigid neural patterns. In general, early findings suggest some patients report reduced distress and improved coping, even when physical sensations remain (8-11).

In medical settings, psychedelics are rarely studied without psychological support. NYU Langone and Johns Hopkins both use structured preparation and follow-up therapy alongside dosing sessions. Clinicians believe this framework is essential because it helps patients interpret experiences and develop healthier responses to pain. Researchers emphasize that medication alone is unlikely to create lasting benefit without therapeutic integration (12-14).

Because psychedelics can produce intense mental effects, safety is a central concern. Hospitals apply strict screening and continuous monitoring during sessions. Institutional review boards oversee every study to ensure informed consent and minimize risk. This controlled environment separates medical research from non-medical or unsupervised use (15-18).

Beyond patient care, medical centers play a key role in shaping the future of pain medicine. Their research provides high-quality data that can inform clinical guidelines, training, and policy decisions. Even when results are mixed, they help clarify which conditions may benefit from, psychedelic-based approaches and which may not (19-21).

Psychedelics research for pain relief is still developing, with a handful of medical centers currently spearheading this work. However, it is garnering increasing attention from clinicians and the public alike. By applying rigorous scientific standards, researchers may be able to transform a controversial topic into a carefully studied area of medicine. Their findings may expand options for patients who continue to struggle with pain and help address the ongoing challenge of providing effective, safe pain management.

References

1. Clinical Trials. Massachusetts General Hospital https://www.massgeneral.org/research/clinical-trials.

2. Dublin, T. C. Psychedelic Research Group – Medicine | Trinity College Dublin. https://www.tcd.ie/medicine/psychiatry/research/psychedelic-research-group/.

3. Psychedelic Medicine. NYU Langone Health https://med.nyu.edu/departments-institutes/psychiatry/research/psychedelic-medicine.

4. The Center for Psychedelic Psychotherapy and Trauma Research | Icahn School of Medicine. https://icahn.mssm.edu/research/center-psychedelic-parsons-research.

5. Psychedelic Research Portal. https://www.psychedelicresearchportal.com/institutes.

6. Clinical & Translational Research | Cleveland Clinic Research. https://www.lerner.ccf.org/clinical/.

7. Clinical Trials & Research Studies | NYU Langone Medical Center. https://clinicaltrials.med.nyu.edu/.

8. Dubner, R. & Gold, M. The neurobiology of pain. PNAS. https://www.pnas.org/doi/10.1073/pnas.96.14.7627. DOI: 10.1073/pnas.96.14.7627

9. Besson, J. M. The neurobiology of pain. Lancet 353, 1610–1615 (1999). DOI: 10.1016/s0140-6736(99)01313-6

10. Conley, M. Fresh consideration given to psychedelics’ therapeutic promise. Stanford Medicine Magazine https://stanmed.stanford.edu/new-consideration-psychedelics-therapy/ (2024).

11. Psychedelic Revolution. https://today.ucsd.edu/story/psychedelic-revolution.

12. Psychedelic Drug Therapy May Address Mental Health Concerns in People with Cancer & Addiction. NYU Langone News https://nyulangone.org/news/psychedelic-drug-therapy-may-address-mental-health-concerns-people-cancer-addiction.

13. Center for Psychedelic & Consciousness Research. Center for Psychedelic & Consciousness Research https://hopkinspsychedelic.org (2020).

14. Gukasyan, N. et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol 36, 151–158 (2022). DOI: 10.1177/02698811211073759

15. Caporuscio, C., Poppe, C., Gieselmann, A. & Repantis, D. Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review. Psychol Med 55, e284 (2025). DOI: 10.1017/S0033291725101761

16. Brittain, N. et al. Ethical Issues and Recommendations in Psychedelic Research and Practice: A Scoping Review. Bioethical Inquiry https://doi.org/10.1007/s11673-025-10454-3 (2025). DOI:10.1007/s11673-025-10454-3.

17. McGuire, A. L. et al. Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Netw Open 7, e2414650 (2024). DOI: 10.1001/jamanetworkopen.2024.14650

18. Robinson, C. L. et al. Ethical Considerations Regarding Psychedelics for Clinical Pain Research. JPR 17, 4357–4364 (2024). DOI: 10.2147/JPR.S491470

19. Askariyan, K. et al. An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 141, 111461 (2025). DOI: 10.1016/j.pnpbp.2025.111461

20. Adams, D. R., Allen, H., Nicol, G. E. & Cabassa, L. J. Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science. Transl Behav Med 14, 744–752 (2024). DOI: 10.1093/tbm/ibae053

21. Kishon, R. et al. A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials. npj Mental Health Res 3, 33 (2024). DOI: 10.1038/s44184-024-00068-9